Interactions of preoperative erythromycin administration with general anaesthesia

Narchi, P.; Benhamou, Dan; Elhaddoury, M.; Locatelli, Carlo; Fernandez, H.

doi:10.1007/bf03009515

Cited by 13 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erythromycin has been shown to be an effective prokinetic agent in patients with diabetes and scleroderma-induced gastric stasis. In addition erythromycin as been demonstrated to be effective in reducing fasting gastric volumes and promoting enteral feeding in the ICU, and may have a place in emergency surgery 33,34 . However its value may be limited by thrombophlebitis, nausea and vomiting, pharmacokinetic interactions with other drugs and cardiac rhythm disturbances (e.g.…”

Section: Pathophysiologymentioning

confidence: 99%

Anti-Aspiration Prophylaxis in New Zealand: A National Survey

Willemsen

1998

Anaesth Intensive Care

View full text Add to dashboard Cite

A postal questionnaire was sent on two occasions to specialist anaesthetists within New Zealand. Questions were related to fasting status, anti-aspiration prophylaxis, incidence of aspiration, definition of high risk groups for aspiration pneumonitis, and identification of departmental guidelines. Two-hundred-and-twenty-three replies were received (72% response rate). Most adults, children and infants were fasted for 6 hours for solids, whilst the majority fasted for 2 to 4 hours for liquids. Two-thirds indicated that they would delay emergency surgery (not life/limb threatening) to optimize gastric emptying. Histamine type 2 receptor antagonists, metoclopramide and cricoid pressure were used commonly, more so in the obstetric population compared to non-obstetric surgery. Preinduction nasogastric intubation and suction were used infrequently. Anti-aspiration prophylaxis was deemed important in morbidly obese patients, those in the third trimester of pregnancy and those with a hiatus hernia, whilst diabetes mellitus, sepsis and renal failure were not considered risk factors for aspiration pneumonitis. 71% of respondents had at least one episode of aspiration (range 0-10), with an overall mortality rate of 5%. Half of these cases of aspiration were deemed to be preventable by the respondent.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Anti-Aspiration Prophylaxis in New Zealand: A National Survey

Willemsen

1998

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal symptoms have not been reported after administration of subtherapeutic doses of oral erythromycin [16,17]. In our study, no patient had such symptoms.…”

Section: Discussionmentioning

confidence: 66%

“…Narchi et al [16] administered erythromycin 500 mg in 125 mL of 5% dextrose IV 30 minutes before induction of anesthesia. In the erythromycin group, residual gastric volume was significantly lower than that of the control group, and no patient had a (article) residual gastric volume greater than 25 mL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of preoperative oral erythromycin, erythromycin-ranitidine, and ranitidine-metoclopramide on gastric fluid pH and volume

Bala¹,

Prasad²,

Bhukal³

et al. 2008

Journal of Clinical Anesthesia

View full text Add to dashboard Cite

“…Other drug–drug interactions described include triazolam with troleandmycin (57), midazolam with erythromycin given orally (58–60) or as a bolus i.v. (61, 62), and roxithromycin with midazolam (63, 64). These results show that interactions involving macrolide antibiotics appears to significantly inhibit the metabolism of BZPs.…”

Section: Pharmacokinetic Interactionsmentioning

confidence: 99%

Clinically significant pharmacokinetic drug interactions with benzodiazepines

Tanaka

1999

J Clin Pharm Ther

View full text Add to dashboard Cite

SUMMARYantibiotics). However, there are few general reviews mainly referring to drug-drug interactions between The reports of interactions between benzodiazepinesBZPs and other drugs that have been published to (BZPs) and other drugs (e.g. antidepressants, sedate (1-4). lective serotonin reuptake inhibitors, antiulcer drugs, Drug interactions can be pharmacokinetic or pharantiepileptic drugs, macrolide antibiotics) during macodynamic in nature. Pharmacodynamic intertheir combined use are reviewed. In general, metaactions occur at biologically active sites (i.e. receptors) bolism of BZPs is delayed when combined with a and change the pharmacological activity of a drug number of other drugs but some reports have sugwithout necessarily altering the kinetics of either agent. gested otherwise.By contrast, in pharmacokinetic interactions, one drug In recent years, the cytochrome P450 (P450 or CYP) specifically affects the blood concentration of another isoenzyme that catalyses the metabolism of BZPs has drug by altering its kinetics (absorption, distribution, also been identified. BZPs are mainly catalysed by metabolism or excretion). As for the mechanisms of CYP3A4. When published reports are studied, it pharmacokinetic interactions, it is desirable to refer to appears necessary to be exceptionally careful about our general remarks (5). interactions mainly between BZPs and selective seroIn this paper, we shall focus on the mechanisms of tonin reuptake inhibitors, cimetidine, antiepileptic metabolic kinetic interactions between BZPs and other drugs, macrolide antibiotics and antimycotics. More drugs, as well as reviewing the evidence for, and information is necessary to identify individuals clinical significance, these interactions. at greatest risk of drug interactions and adverse events.

show abstract

Interactions of preoperative erythromycin administration with general anaesthesia

Cited by 13 publications

References 11 publications

Anti-Aspiration Prophylaxis in New Zealand: A National Survey

Anti-Aspiration Prophylaxis in New Zealand: A National Survey

Effect of preoperative oral erythromycin, erythromycin-ranitidine, and ranitidine-metoclopramide on gastric fluid pH and volume

Clinically significant pharmacokinetic drug interactions with benzodiazepines

Contact Info

Product

Resources

About